Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 12,500 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 12,500 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $18.68, for a total value of $233,500.00. Following the completion of the sale, the chief operating officer owned 189,141 shares of the company’s stock, valued at $3,533,153.88. This represents a 6.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Ryan Cohlhepp also recently made the following trade(s):

• On Friday, November 21st, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.05, for a total value of $225,625.00.
• On Wednesday, October 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.16, for a total value of $227,000.00.
• On Tuesday, October 7th, Ryan Cohlhepp sold 10,900 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.06, for a total value of $196,854.00.
• On Monday, October 6th, Ryan Cohlhepp sold 39,600 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.06, for a total transaction of $715,176.00.

Bicara Therapeutics Stock Down 1.1%

Bicara Therapeutics stock traded down $0.21 on Tuesday, hitting $18.15. The company’s stock had a trading volume of 559,497 shares, compared to its average volume of 608,338. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $19.75. The firm has a market cap of $994.29 million, a P/E ratio of -8.10 and a beta of -0.87. The company has a fifty day moving average price of $17.06 and a 200-day moving average price of $13.26.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). Analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Trading of Bicara Therapeutics

Large investors have recently made changes to their positions in the business. Legal & General Group Plc increased its stake in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after buying an additional 1,474 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares during the last quarter. Larson Financial Group LLC increased its position in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its position in Bicara Therapeutics by 119.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock valued at $75,000 after acquiring an additional 4,417 shares in the last quarter.

Analyst Ratings Changes

BCAX has been the topic of a number of recent research reports. Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Tuesday, October 14th. Piper Sandler assumed coverage on Bicara Therapeutics in a research note on Monday, August 18th. They issued an “overweight” rating and a $36.00 price target on the stock. Wells Fargo & Company upped their price target on Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Finally, HC Wainwright dropped their price objective on Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, August 22nd. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bicara Therapeutics has an average rating of “Moderate Buy” and an average target price of $29.67.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.